In this review, we discuss recently identified GBM biomarkers, such as ADAMTSL4 and ACSS3, and metabolic proteins associated with GBM immune suppression and poor prognosis and their potential to stratify patients for immunotherapy. The gene discussed is ADAMTSL4; the disease is glioblastoma.